Abstract
Background: Sleep bruxism (SB) management aims to reduce the number and magnitude of bruxism episodes per hour of a patient’s sleep and, therefore, reduce the potentially negative clinical consequences. Opipramol belongs to the group of tricyclic antidepressants (TCAs) and is considered as an atypical TCA, as it acts primarily as a sigma receptor agonist. This study aimed to preliminarily determine the effectiveness of opipramol in the management of severe SB. Methods: A total of 19 otherwise healthy participants with severe SB diagnosed during stage I video polysomnography (vPSG) were subjected to an 8-week pharmacotherapy trial with a 100 mg bedtime daily dose of opipramol and were then analyzed by control stage II vPSG. Results: The participants included 14 females and 5 males, aged 20–47 years (mean ± standard deviation: 32.32 ± 8.12). A comparison of stage I and II vPSG recordings showed a decrease in all the studied SB parameters in 78.85% of participants. Only in a small group of participants (15.53%) was a non-significant increase of SB parameters observed. Conclusions: A single 100 mg dose of opipramol at bedtime seems to positively affect the reduction of SB in otherwise healthy individuals diagnosed with severe SB. However, the subject requires further research on a larger population including a control group.
Highlights
In accordance with the 2018 International Consensus, sleep bruxism (SB) and awake bruxism are considered as two separate phenomena [1]
Thirty otherwise healthy adult participants diagnosed with severe Sleep bruxism (SB) during stage I
VPSG (BEI > 4) were included in the study. They were subjected to a clinical reevaluation after 4 weeks of the opipramol pharmacotherapy to observe for side effects caused by the drug intake
Summary
In accordance with the 2018 International Consensus, sleep bruxism (SB) and awake bruxism are considered as two separate phenomena [1]. SB is defined as a masticatory muscle activity that can be either phasic (rhythmic) or tonic (non-rhythmic) and is not a movement disorder or a sleep disorder in otherwise healthy individuals [1]. In some individuals, for example, those with obstructive sleep apnea (OSA), epilepsy, rapid eye movement (REM) sleep behavior disorder, or gastroesophageal reflux disease, SB can be considered as a sign of a disorder [1,2,3,4,5]. Methods: A total of 19 otherwise healthy participants with severe SB diagnosed during stage I video polysomnography (vPSG) were subjected to an 8-week pharmacotherapy trial with a 100 mg bedtime daily dose of opipramol and were analyzed by control stage II vPSG. Conclusions: A single 100 mg dose of opipramol at bedtime seems to positively affect the reduction of SB in otherwise healthy individuals diagnosed with severe SB. The subject requires further research on a larger population including a control group
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
